Statins and the acute coronary syndrome: 'The early bird catches the worm'

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 716-727

  Nair, P ^a   Roguin, Ariel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Coagulation; Coronary artery disease; Lipids; Risk reduction; Therapy

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; THROMBOXANE A2;

ACUTE CORONARY SYNDROME; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOCHEMISTRY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; FIBRINOLYSIS; HISTOLOGY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECURRENCE RISK; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; UNSPECIFIED SIDE EFFECT;

C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SYNDROME; THROMBOXANE A2;

EID: 33744541341     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00856.x     Document Type: Article

References (70)

1. Winter RJ, Windhausen F, Cornel JH et al. Early invasive versus selectively invasive management for acute coronary syndromes. New Engl J Med 2005; 353: 1095-104.
2. Fox KA, Poole-Wilson PA, Henderson RA et al. for the Randomized Intervention Trial of unstable Angina (RITA) investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart foundation RITA 3 randomised trial. Lancet 2002; 360: 743-51.
3. Group SSSS. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
6. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
8. Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. Lancet 2005; 365: 1779-85.
9. Blauw GJ, Lagaay AM, Smelt AH et al. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-50.
10. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155: 50-5.
11. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2000; 102: 1193-209.
12. Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24.
13. Cohen M, Antman EM, Murphy SA et al. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Am Heart J 2002; 143: 63-9.
14. Antman E, Cohen M, Radley D et al. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
15. Rioufol G, Finet G, Ginon I et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002; 106: 804-8.
16. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524-34.
17. Lacoste L, Lam JY, Hung J et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
18. Dangas G, Badimon JJ, Smith DA et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-304.
19. Marmur JD, Thiruvikraman SV, Fyfe BS et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-32.
20. Ardissino D, Merlini PA, Ariens R et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-71.
21. Eto M, Kozai T, Cosentino F et al. Statin prevents tissue factor expression in human endothelial cells. Role of Rho/Rho kinase Akt pathways. Circulation 2002; 105: 1756.
22. van Willigen G, Gorter G, Akkerman JW. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994; 14: 41-6.
23. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins-implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
24. Laufs U, Gertz K, Huang P et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2437-49.
25. Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999; 33: 1305-7.
26. Bonetti PO, Lerman LO, Napoli C et al. Statin effects beyond lipid lowering - Are they clinically relevant? Eur Heart J 2003; 24: 225-48.
27. Notarbartolo A, Davi G, Averna M et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscleros Thromb Vasc Biol 1995; 15: 247-51.
28. Stroes ES, Koomans HA, de Bruin TW et al. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-71.
29. Dupuis J, Tardif JC, Cernacek P et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.
30. Falk E. Why do plaques rupture? Circulation 1992; 86 (Suppl. III): 30-42.
31. Ridker P, Rifai N, Pfeffer MA. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
32. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation 2001; 103: 926-33.
33. Williams JK, Sukhova GK, Herrington DM et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91.
34. Bellosta S, Via D, Canavesi M et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
35. Ridker P, Rifai N, Pfeffer MA et al for the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentrations of C-reactive protein. Circulation 1999; 100: 230-5.
36. Kinlay S, Rifai N, Libby P et al. Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: A substudy of the MIRACL trial. J Am Coll Cardiol 2000; 39: 304A.
37. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-52.
38. Jialal I, Stein D, Balis D et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein. Circulation 2001; 103: 1933-5.
39. Stenestrand U, Wallentin L for the Swedish Register of Cardiac Intensive Care (RISKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6.
40. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-8.
41. Giugliano RP, Antman EM, Thompson SL et al. Lipid-lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality (Abstract). Jam Coll Cardiol 2001; 37 (Suppl.): A316.
42. Cannon CP, McCabe CH, Bentley J et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16. J Am Collcardiol 2001; 37 (Suppl.): A334.
43. Heeschen C, Hamm CW, Laufs U et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
44. Arntz HR, Wunderlich W, Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after and acute coronary event: Short and long-term results of a controlled study. Circulation 1998; 98 (Suppl. 1): 1-45.
45. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-8.
46. Cannon CP, McCabe CH, Belder R et al. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002; 89: 860-1.
47. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
48. Blazing MA, De Lemos JA, Dyke CK et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142: 211-7.
49. Nissen SE. High-dose statins in acute coronary syndromes: Not just lipid levels. JAMA 2004; 292: 1365-7.
50. Newby LK, Kristinsson A, Bhapkar MV et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287: 3087-95.
51. LaBlanche J-M, Wright RS, Wouter J et al. Reductions in early recurrent coronary ischemia from early administration of statin therapy upon admission for myocardial infarction: Results of the PRINCESS trial. Circulation 2004; 110: III-498.
52. Ostadal P, Alan D, Hajek P et al. Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial). Curr Control Trials Cardiovasc Medical 2005; 6: 4.
53. IMPROVE-IT. Examining Outcomes in Subjects with Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103) ClinicalTrials.gov Identifier: NCT00202878.
54. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
55. Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 1997; 96: 1398-402.
56. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
57. Weber C, Erl W, Weber KS et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.
58. Davidson MH, Nawrocki JW, Weiss SR et al. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol 1997; 80: 347-8.
59. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
60. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 2002; 360: 1623-30.
61. Asakura M, Ueda Y, Yamaguchi O et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study. J Am Coll Cardiol 2001; 37: 1284-8.
62. Goldstein JA, Demetriou D, Grines CL et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-22.
63. van Vliet AK, van Thiel GC, Huisman RH et al. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995; 1254: 105-11.
64. Koga T, Shimada Y, Kuroda M et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 115-20.
65. Yamazaki M, Suzuki H, Hanano M et al. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993; 264 (Pt 1): G36-44.
66. Inoue I, Goto S, Mizotani K et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor a (PPARa) in primary endothelial cells. Life Sci 2000; 67: 863-76.
67. Nègegre-Aminou P, van Vliet AK, van Erck M et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-68.
68. Corsini A, Mazzotti M, Raiteri M et al. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25.
69. Guijarro C, Blanco-Colio LM, Ortego M et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
70. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000; 35: 256-62.